Replies to post #96710 on Biotech Values

[DewDiligence]

Tasigna-vs-Gleevec phase-3 GIST study halted for futility:

http://www.novartis.com/newsroom/media-releases/en/2011/1504991.shtml

The study was halted because Tasigna had little chance to show statsig superiority to Gleevec in PFS, the primary endpoint. The GIST failure is somewhat surprising insofar as Tasigna bested Gleevec with ease in first-line CML (#msg-50898190).

The description of the GIST study is at: http://clinicaltrials.gov/ct2/show/NCT00785785 .